HIPEC Surgery in India for Canadian Patients

Author:- Dr. Dheeraj Bojwani Date Created:- 11-08-2026

Key Takeaways

• Canada has only four major centres performing CRS-HIPEC nationally, according to the PDF. The guide highlights that access is particularly limited in provinces such as Newfoundland and Labrador, where no CRS-HIPEC programme exists.
• CRS-HIPEC combines cytoreductive surgery, which removes visible tumour from the abdominal cavity, with heated chemotherapy delivered directly into the abdomen to target microscopic residual disease. It may be considered for selected patients with peritoneal spread from colorectal, appendiceal, ovarian or gastric cancer and peritoneal mesothelioma.
• The procedure is technically demanding and may take eight to twelve hours. The PDF emphasizes that completeness of cytoreduction—the extent to which visible tumour is removed—is a particularly important factor in outcomes.
• The page 2 chart compares the Canadian competency floor of 12 CRS-HIPEC cases per year with an illustrative high-volume international centre performing approximately 150 cases per year. The guide stresses that 12 cases is a minimum competency threshold, not a marker of excellence.
• CRS-HIPEC is not suitable for every patient with peritoneal spread. The guide says it generally works best for limited, resectable disease, assessed using a formal peritoneal cancer index, and may not be appropriate for extensive disease, significant disease outside the abdomen or patients unable to tolerate a prolonged operation and recovery.
• The page 4 cost visual gives an indicative India CRS-HIPEC surgical-package cost of approximately C$24,500, compared with approximately C$225,000 for private treatment in the United States.
• Patients should evaluate a centre's annual CRS-HIPEC caseload, the individual surgeon's experience, formal peritoneal cancer index assessment, dedicated ICU and perioperative pathways, accreditation and quality of discharge documentation rather than choosing based on price alone.
• The guide recommends planning for approximately four to five weeks in India, using a changeable ticket and obtaining documented fit-to-fly clearance before returning to Canada.

Quick Facts

Treatment

CRS-HIPEC Surgery

Country

India

Patients

Canadian Patients

Specialty

Peritoneal Surface Oncology / Surgical Oncology

CRS-HIPEC Centres in Canada

4 Major Centres

Main Cancer Types

Colorectal, Appendiceal, Ovarian and Gastric Cancer; Peritoneal Mesothelioma

Treatment Approach

Cytoreductive Surgery Followed by Heated Intraperitoneal Chemotherapy

Typical Operation Duration

Approximately 8–12 Hours

Key Assessment

Peritoneal Cancer Index and Disease Resectability

Canadian Competency Floor

12 Cases Per Year

Illustrative High-Volume Centre

Approximately 150 Cases Per Year

Hospital Selection

Dedicated Perioperative/ICU Pathway and Verifiable Accreditation

Follow-Up

Canadian Oncologist With Complete Surgical and Treatment Records

Important Principle

Confirm Candidacy Through a Specialist Peritoneal Disease Team

In Brief

For Canadian patients with peritoneal spread from an appropriate primary cancer, the most important question is whether a specialist peritoneal disease team has formally assessed the disease for CRS-HIPEC, rather than simply comparing treatment prices. Because the procedure is highly specialised and concentrated in only a few Canadian centres, a second opinion from a high-volume peritoneal disease centre in India may be considered when appropriate.

The rarest, most concentrated treatment in this entire series

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, CRS-HIPEC, removes visible tumour from the abdominal cavity and then bathes it in heated chemotherapy, treating microscopic disease the surgeon cannot see. For selected patients with peritoneal spread from colorectal, appendiceal, ovarian or gastric cancer, or from peritoneal mesothelioma, it is genuinely the standard of care. In 24 years of guiding international patients into Indian hospitals, this is the procedure where I most often find the problem is not treatment quality. It is that the patient was never told the treatment existed for their situation.

Published Canadian research on peritoneal mesothelioma identified four major peritoneal disease centres treating this condition nationally, across the entire country. A feasibility study specifically examining Newfoundland and Labrador confirmed the province has no CRS-HIPEC programme at all. This is not a wait-time story in the way most of this series has been. It is a geography and awareness story: an entire category of curative-intent treatment that simply does not exist in large parts of Canada, delivered by clinicians who, understandably, do not think to raise a procedure their own province cannot provide.

Why volume matters more here than almost anywhere else in oncology

CRS-HIPEC is a long, technically demanding operation, often eight to twelve hours, and the single most important predictor of outcome is how completely the visible tumour is removed — what surgeons call the completeness of cytoreduction. Achieving that consistently depends on experience in a way few other cancer operations do.

The Canadian HIPEC Collaborative Group itself recommends a minimum of one case a month, twelve a year, for a centre to maintain competency in this procedure. That is stated explicitly as a floor for adequacy, not a marker of excellence. Dedicated high-volume international peritoneal disease centres, including several in India, routinely operate at several multiples of that minimum, concentrating the kind of experience that shows up directly in completeness-of-cytoreduction rates and long-term survival.

The gap that should worry you most: not the wait, the referral

Because this treatment is genuinely rare and technically specialised, most oncologists, including excellent ones, encounter it only occasionally in their own practice. That creates a specific, well-documented failure mode internationally: patients diagnosed outside an expert peritoneal disease centre are measurably less likely to ever be referred for CRS-HIPEC evaluation at all, independent of whether they were medically appropriate for it.

Canada does not publish an equivalent national figure, but the mechanism is not unique to any one country. A rare, specialised treatment that most general oncologists see only a handful of times in a career is easy to under-refer for, particularly outside the small number of centres where it is routine. If you have peritoneal disease from an appropriate primary cancer and CRS-HIPEC has never explicitly been discussed and ruled out by a peritoneal disease specialist, that omission itself is worth raising directly with your oncologist.

Who this actually applies to

CRS-HIPEC is not appropriate for every patient with peritoneal spread. It works best for limited, resectable disease, assessed using a formal peritoneal cancer index, and is generally not appropriate for extensive disease, significant disease outside the abdominal cavity, or a patient too unwell to tolerate a long operation and recovery. This determination should be made by a specialist peritoneal disease team, not inferred from a general oncology opinion alone — which is precisely why the referral gap above matters as much as it does.

What the money actually looks like

CRS-HIPEC is not something Canada's small private surgical sector offers at any price; it requires specialised heated-perfusion equipment, a dedicated peritoneal disease surgical team, and an extended intensive care stay that a boutique clinic simply cannot provide. For a patient exploring options beyond the four national centres, the realistic paid alternative is the United States rather than a domestic clinic.

American CRS-HIPEC, priced for an insurance-backed domestic market, commonly runs into six figures once insurance is not in the picture. India's major peritoneal disease centres perform this operation at high volume, with dedicated teams and the same completeness-of-cytoreduction discipline described above, at a fraction of the American price. In 24 years of guiding patients through decisions like this, the question I ask first is never the price. It is whether a genuine peritoneal disease specialist, not a general oncologist, has actually reviewed the imaging and confirmed the disease is resectable.

What you are actually getting for it

Genuine, checkable peritoneal-disease-specific volume. Ask for the unit's annual CRS-HIPEC caseload and the operating surgeon's own volume, separately from general oncological surgery numbers.

Formal peritoneal cancer index scoring and a real resectability assessment, not an assumption based on a scan report alone.

A dedicated perioperative and ICU pathway built for this specific operation, including nutritional optimisation before surgery, which meaningfully affects recovery from an operation this extensive.

Accreditation you can verify independently. JCI is the international arm of the body accrediting hospitals across the United States; NABH is India's national equivalent, recognised by the same global standards authority.

A discharge record built for your Canadian oncologist to use, including the completeness-of- cytoreduction score, chemotherapy agents used, and a specific surveillance and adjuvant treatment plan.

Four Things that Should Make You Walk Away Immediately

Straight answers

A closing word

CRS-HIPEC is not a treatment most Canadians with peritoneal disease will be offered as a matter of course, not because it wouldn't help, but because the country's capacity to deliver it is genuinely thin and concentrated in four centres for the whole population. If you have not had a specific, explicit conversation with a peritoneal disease specialist about whether you are a candidate, that conversation is worth having before anything else. If you would like a second opinion on your imaging, send it to me and I will look at it properly.

Sources

• 🌐 "Feasibility of a HIPEC Program for Gastrointestinal and Gynecological Cancer Care in Newfoundland and Labrador" — mdpi.com/2673-7523/5/2/16
• 🌐 "Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes" — pubmed.ncbi.nlm.nih.gov/37249154
• 🌐 "A Canadian single-centre experience with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for abdominal malignancies", Canadian Journal of Surgery — canjsurg.ca/content/65/3/E342
• 🌐 "Towards Equal Access to Cytoreductive Surgery with HIPEC in Patients with Isolated Colorectal Peritoneal Metastases: A Nationwide Population-Based Study" — ncbi.nlm.nih.gov/pmc/articles/PMC11076384
• 🌐 High Commission of India, e-Visa categories and eligibility — indianvisaonline.gov.in/evisa

Frequently Asked Questions

What is CRS-HIPEC surgery?

CRS-HIPEC combines cytoreductive surgery to remove visible abdominal tumour with heated chemotherapy delivered directly into the abdominal cavity to treat microscopic disease.

Which cancers may be treated with HIPEC?

The guide discusses selected cases involving colorectal, appendiceal, ovarian and gastric cancers, as well as peritoneal mesothelioma when the disease pattern is appropriate.

How many CRS-HIPEC centres are available in Canada?

The PDF identifies four major peritoneal disease centres treating this condition nationally. It also notes that Newfoundland and Labrador has no CRS-HIPEC programme.

How is CRS-HIPEC candidacy determined?

A specialist team assesses disease distribution using a peritoneal cancer index and determines whether the disease can be adequately resected. Overall fitness for a long operation is also considered.

Why is surgeon and hospital volume important for HIPEC?

CRS-HIPEC is a technically demanding operation that can last eight to twelve hours. The guide emphasizes that experience is particularly important for achieving complete cytoreduction consistently.

How much does HIPEC cost in India?

The PDF gives an indicative India CRS-HIPEC surgical-package cost of approximately C$24,500, compared with approximately C$225,000 for private treatment in the United States.

How long should Canadian patients plan to stay in India?

The guide recommends planning for approximately four to five weeks, depending on recovery and fit-to-fly clearance.

What should make a patient reconsider a HIPEC centre?

Warning signs include a treatment recommendation without formal peritoneal cancer index assessment, promises to operate despite extensive disease, unclear CRS-HIPEC volume and pressure to decide quickly or exclude the Canadian oncologist from communication.

Will a Canadian provincial plan reimburse HIPEC performed in India?

Almost never. The guide notes that out-of-country coverage generally requires pre-approval and evidence that the procedure is genuinely unavailable in Canada within a medically acceptable time.

Who manages follow-up after returning to Canada?

The Canadian oncologist should manage follow-up using the surgical records, completeness-of-cytoreduction score, chemotherapy details and specific surveillance plan prepared before the patient leaves India.

Page Summary

This guide explains CRS-HIPEC surgery in India for Canadian patients with selected peritoneal cancers. It highlights Canada's limited access, with only four major centres nationally, and explains why referral and awareness can be a greater barrier than waiting time. The guide describes patient selection using the peritoneal cancer index and disease resectability, emphasizes the importance of high-volume specialist teams, and compares indicative India and US costs. It also recommends approximately four to five weeks in India and stresses detailed communication and follow-up with the Canadian oncology team.

Citation Block

Topic	Information
Topic	HIPEC Surgery in India for Canadian Patients
Treatment	CRS-HIPEC
Country	India
Intended Audience	Canadian Patients
Specialty	Peritoneal Surface Oncology / Surgical Oncology
Canadian CRS-HIPEC Centres	4 Major Centres
Cancer Types	Colorectal, Appendiceal, Ovarian, Gastric and Peritoneal Mesothelioma
Treatment Method	Cytoreductive Surgery + Heated Intraperitoneal Chemotherapy
Operation Duration	Approximately 8–12 Hours
Key Assessment	Peritoneal Cancer Index and Resectability
Canadian Competency Floor	12 Cases Per Year
Key Selection Factor	Specialist Peritoneal Disease Assessment
Author	Dr. Dheeraj Bojwani
Experience	24+ Years